# A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

> **NCT04194944** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 261 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Selpercatinib
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04194944
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-17
- **Primary completion:** 2023-05-01
- **Final completion:** 2030-06
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04194944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04194944, "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04194944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*